• 1 aFaculty of Medicine, Centre of Excellence for Research in AIDS (CERiA), University of Malaya, Kuala Lumpur, Malaysia bNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA cFaculty of Medicine, Tropical Infectious Diseases Research and Education Centre (TIDREC), Department of Medical Microbiology dInfectious Disease Unit, Department of Medicine, University of Malaya Medical Centre, Kuala Lumpur, Malaysia eNational Institute for Research in Tuberculosis, Chennai, India fCentre for Biomedical Research, Macfarlane Burnet Institute for Medical Research and Public Health gInfectious Diseases Unit, The Alfred Hospital hDepartment of Infectious Diseases, Monash University, Melbourne iSchool of Pathology and Laboratory Medicine, University of Western Australia jDepartment of Clinical Immunology, Royal Perth Hospital and PathWest Laboratory Medicine, Perth, Western Australia, Australia
AIDS, 2015 Feb 20;29(4):421-31.
PMID: 25565499 DOI: 10.1097/QAD.0000000000000557


Tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) is a substantial problem in HIV/TB coinfected patients commencing antiretroviral therapy (ART). The immunopathogenesis of TB-IRIS includes increased production of proinflammatory chemokines and cytokines, including interleukin-18, which is a signature cytokine of the nucleotide-binding domain and leucine-rich repeat pyrin containing protein-3 inflammasome. We compared plasma levels of interleukin-18 and other biomarkers of monocyte/macrophage activation in the prediction and characterization of TB-IRIS.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.